← Back to all trials
Completed
NCT06267846
A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder
Conditions: Major Depressive Disorder
Sex: All
Ages: 18 Years – 65 Years
Healthy volunteers: No
Phase: PHASE2
Enrollment: 73
Sponsor: Neurocrine Biosciences
Location: Neurocrine Clinical Site Little Rock Arkansas
Summary
To evaluate the efficacy, safety, and tolerability of NBI-1070770 compared to placebo on improving symptoms of depression in participants with major depressive disorder (MDD).
Eligibility Criteria
Key Inclusion Criteria:
Participants must meet all of the following inclusion criteria:
* Primary diagnosis of recurrent MDD or persistent MDD.
* Participants currently receiving pharmacological treatment for depression must have been taking current antidepressant medication(s) for ≥8 weeks prior to screening and must be willing and able to continue with current antidepressant medication(s).
* Participants must be willing and able to comply with all study procedures and restrictions.
Key Exclusion Criteria:
Participants will be excluded from the study if they meet any of the following criteria:
* Participant is pregnant or breastfeeding or plan to become pregnant during the study.
* Participant has an unstable medical condition or unstable chronic disease.
* Participant has a history of neurological abnormalities.
* Participant has a current or prior psychiatric disorder diagnosis that was the primary focus of treatment other than MDD.
* Participant's depressive symptoms have previously demonstrated nonresponse to an adequate course of treatment with electroconvulsive therapy.
* Participant has an alcohol or substance use disorder.
Note: Other inclusion/exclusion criteria may apply
Source: ClinicalTrials.gov (NCT06267846). StuddyBuddy aggregates publicly available trial information.